EP1140906A4 - Imidazolones and their use in treating benign prostatic hyperplasia and other disorders - Google Patents

Imidazolones and their use in treating benign prostatic hyperplasia and other disorders

Info

Publication number
EP1140906A4
EP1140906A4 EP99965317A EP99965317A EP1140906A4 EP 1140906 A4 EP1140906 A4 EP 1140906A4 EP 99965317 A EP99965317 A EP 99965317A EP 99965317 A EP99965317 A EP 99965317A EP 1140906 A4 EP1140906 A4 EP 1140906A4
Authority
EP
European Patent Office
Prior art keywords
imidazolones
disorders
benign prostatic
prostatic hyperplasia
treating benign
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99965317A
Other languages
German (de)
French (fr)
Other versions
EP1140906A1 (en
Inventor
Wai C Wong
T G Murali Dhar
Charles Gluchowski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synaptic Pharmaceutical Corp
Original Assignee
Synaptic Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synaptic Pharmaceutical Corp filed Critical Synaptic Pharmaceutical Corp
Publication of EP1140906A1 publication Critical patent/EP1140906A1/en
Publication of EP1140906A4 publication Critical patent/EP1140906A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
EP99965317A 1998-12-17 1999-12-17 Imidazolones and their use in treating benign prostatic hyperplasia and other disorders Withdrawn EP1140906A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/213,078 US6046331A (en) 1998-12-17 1998-12-17 Imidazolones and their use in treating benign prostatic hyperplasia and other disorders
US213078 1998-12-17
PCT/US1999/030260 WO2000035907A1 (en) 1998-12-17 1999-12-17 Imidazolones and their use in treating benign prostatic hyperplasia and other disorders

Publications (2)

Publication Number Publication Date
EP1140906A1 EP1140906A1 (en) 2001-10-10
EP1140906A4 true EP1140906A4 (en) 2002-03-13

Family

ID=22793661

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99965317A Withdrawn EP1140906A4 (en) 1998-12-17 1999-12-17 Imidazolones and their use in treating benign prostatic hyperplasia and other disorders

Country Status (6)

Country Link
US (1) US6046331A (en)
EP (1) EP1140906A4 (en)
JP (1) JP2002532491A (en)
AU (1) AU769186C (en)
CA (1) CA2355202A1 (en)
WO (1) WO2000035907A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9902765D0 (en) 1999-07-21 1999-07-21 Astra Pharma Prod Novel compounds
GB0028484D0 (en) * 2000-11-22 2001-01-10 Hoffmann La Roche Imidazolone derivatives for the treatment of viral diseases
CN107815438A (en) * 2017-08-02 2018-03-20 清华大学 Recombinant cell, screen the purposes and pharmaceutical composition of the method, reagent of L-type calcium channel modulators in medicine is prepared

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61191681A (en) * 1985-02-21 1986-08-26 Fujisawa Pharmaceut Co Ltd 4-imidazolin-2-one derivative
WO1997003067A1 (en) * 1995-07-13 1997-01-30 Knoll Aktiengesellschaft Piperazine derivatives as therapeutic agents
WO1998057940A1 (en) * 1997-06-18 1998-12-23 Synaptic Pharmaceutical Corporation Heterocyclic substituted piperidines and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3362956A (en) * 1965-08-19 1968-01-09 Sterling Drug Inc 1-[(heterocyclyl)-lower-alkyl]-4-substituted-piperazines
JPS6153281A (en) * 1984-08-24 1986-03-17 Kotobuki Seiyaku Kk 1,3-substituted-2-imidazolidinone derivative, promoter for gastrointestinal motion and its preparation
IT1230703B (en) * 1989-01-26 1991-10-29 Luso Farmaco Inst IMIDAZOLONIC DERIVATIVES WITH ANTI-HYPERTENSIVE ACTIVITY, THEIR PREPARATION METHODS AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
FR2672052B1 (en) * 1991-01-28 1995-05-24 Esteve Labor Dr DERIVATIVES OF ARYL (OR HETEROARYL) -PIPERAZINYL-ALKYL-AZOLES, THEIR PREPARATION AND THEIR APPLICATION AS MEDICAMENTS.
FR2673628B1 (en) * 1991-03-07 1993-07-09 Esteve Labor Dr PROCESS FOR THE PREPARATION OF ARYL (OR HETEROARYL) -PIPERAZINYL-BUTYL-AZOLES DERIVATIVES.
US5428037A (en) * 1993-04-09 1995-06-27 Syntex Pharmaceuticals, Ltd. Heterocyclic derivatives in the treatment of Ischaemia and related diseases
FR2723091B1 (en) * 1994-07-29 1996-11-08 Esteve Labor Dr TETRAHYDROPYRIDINE- (6,4-HYDROXYPIPERIDINE) ALKYLAZOLES
DE4439846A1 (en) * 1994-11-08 1996-05-09 Merck Patent Gmbh Adhesion receptor antagonists
US5478934A (en) * 1994-11-23 1995-12-26 Yuan; Jun Certain 1-substituted aminomethyl imidazole and pyrrole derivatives: novel dopamine receptor subtype specific ligands
FR2742052B1 (en) * 1995-12-12 1998-04-10 Esteve Labor Dr USE OF DERIVATIVES 1- (4- (4-ARYL (OR HETEROARYL) -1-PIPER AZINYL) -BUTY) -1H-AZOLE FOR THE TREATMENT OF DEPRESSION, OBSESSIVE COMPULSIVE DISORDERS, SLEEP APNEA, SEXUAL DYSFUNCTIONS , Emese and motion sickness
US5872136A (en) * 1996-04-03 1999-02-16 Merck & Co., Inc. Arylheteroaryl inhibitors of farnesyl-protein transferase

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61191681A (en) * 1985-02-21 1986-08-26 Fujisawa Pharmaceut Co Ltd 4-imidazolin-2-one derivative
WO1997003067A1 (en) * 1995-07-13 1997-01-30 Knoll Aktiengesellschaft Piperazine derivatives as therapeutic agents
WO1998057940A1 (en) * 1997-06-18 1998-12-23 Synaptic Pharmaceutical Corporation Heterocyclic substituted piperidines and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PATENT ABSTRACTS OF JAPAN vol. 011, no. 018 (C - 398) 17 January 1987 (1987-01-17) *

Also Published As

Publication number Publication date
AU3126200A (en) 2000-07-03
WO2000035907A1 (en) 2000-06-22
JP2002532491A (en) 2002-10-02
AU769186B2 (en) 2004-01-22
AU769186C (en) 2005-02-17
EP1140906A1 (en) 2001-10-10
US6046331A (en) 2000-04-04
CA2355202A1 (en) 2000-06-22

Similar Documents

Publication Publication Date Title
SI0968208T1 (en) Quinoline and quinazoline compounds useful in therapy, particularly in the treatment of benign prostatic hyperplasia
EP0924983A4 (en) S(-)-tolterodine in the treatment of urinary and gastrointestinal disorders
IL141235A0 (en) Combined use of an alpha-adrenoceptor antagonist and amuscarinic antagonist in the treatment of benign prostatic hyperplasi
AU1316000A (en) Compositions and methods for treating benign prostatic hyperplasia using tocotrienols
NO992069L (en) Conjugates that can be used in the treatment of prostate cancer
ZA972600B (en) Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
EP0855910A4 (en) Conjugates useful in the treatment of benign prostatic hyperplasia
IL132836A0 (en) Arylsubstituted piperazines useful in the treatment of benign prostatic hyperplasia
PL340768A1 (en) Conjugates useful in treating prostatic carcinoma
HK1030776A1 (en) Substituted pyridino arylpiperazines useful in the treatment of benign prostatic hyperplasia
ZA982819B (en) Treatment or prophylaxis of prostatic cancer and benign prostatic hyperplasia with selective estrogn receptor modulators.
ZA981781B (en) The use of levobupivacaine in treating migraine
EP1140906A4 (en) Imidazolones and their use in treating benign prostatic hyperplasia and other disorders
AU6570998A (en) Prostate specific antigen from benign prostatic hyperplasia and its use in diagnosis
PL337665A1 (en) (s) 2-methylamine-2-phenyl-n-butyl-3,4,5-trimethoxybezoate and application thereof in treating long-lasting pains
ZA991319B (en) Novel phthalimido arylpiperazines useful in the treatment of benign prostatic hyperplasia.
EP0748627A3 (en) Melatonin agonists for use in the treatment of benign prostatic hyperplasia
GB9602903D0 (en) Conjugates useful in the treatment of benign prostatic hyperplasia
AU2003204320A1 (en) Heterocycles useful in the treatment of benign prostatic hyperplasia and intermediates thereof
AU2002300904A1 (en) Arylsubstituted piperazines useful in the treatment of benign prostatic hyperplasia
AU2002232403A1 (en) Del-1 and benign prostatic hyperplasia
SI0925069T1 (en) Use of cetrorelix for the treatment of benign prostate hypertrophy and prostate cancer
GB9810895D0 (en) Combination therapy for the treatment of benign prostatic hyperplasia
ZA98793B (en) Microparticles and their use in cancer treatment

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010717

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

RIN1 Information on inventor provided before grant (corrected)

Inventor name: GLUCHOWSKI, CHARLES

Inventor name: DHAR, T., G., MURALI

Inventor name: WONG, WAI, C.

A4 Supplementary search report drawn up and despatched

Effective date: 20020124

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7C 07D 233/70 A, 7C 07D 401/06 B, 7C 07D 401/08 B, 7C 07D 471/20 B, 7C 07D 405/14 B, 7A 61K 31/4166 B, 7A 61P 13/08 B

17Q First examination report despatched

Effective date: 20030310

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040907